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Ian Nivison -Smith,1 Judy M. Simpson,2 Anthony J. Dodds,3 David D. F. Ma,3
Jeff Szer,4 Kenneth F. Bradstock5Whether the annual mortality rates of long-term hematopoietic cell transplant (HCT) survivors ever return
to that of the general population is unclear. This study sought to determine the annual long-term mortality
rates of allogeneic and autologous HCTrecipients who had survived 5 years or more disease-free posttrans-
plant and calculate their relative survival rates. Patients were included if they had a first allogeneic or synge-
neic HCT for acute leukemia, chronic myelogenous leukemia (CML) or myelodysplastic syndromes (MDS),
or autologous HCT for acute myelogenous leukemia (AML) or lymphoma in Australia or New Zealand
between 1992 and 2001, recorded on the Australasian Bone Marrow Transplant Recipient Registry
(ABMTRR) database, and were known to have survived, disease free, 5 years or more posttransplant. The
annual mortality rates of 5-year transplant survivors were compared to standard Australian and New Zea-
land populations using relative survival. A total of 1461 HCT survivors (688 postallograft, 773 postautograft)
were included in this study. The 10-year survival probability for 5-year allograft survivors was slightly higher
than that of 5-year autologous survivors (93.4% versus 89.6%, P5.06). The relative survival of both alloge-
neic and autologous 5-year survivors was never\97% of that of the general population. However, it was
statistically significantly lower than expected in the sixth to ninth years posttransplant, with no obvious pat-
tern of either improvement or deterioration from 6 to 10 years posttransplant. This study indicates that an-
nual relative survival rates of long-term survivors of allogeneic HCT performed in Australia andNewZealand
for acute lymophoblastic leukemkia (ALL), AML, CML, and MDS are slightly, but significantly lower than
population rates in the 6th to 10th years posttransplant. Annual relative survival rates of long-term survivors
of autologous HCT performed in Australia and New Zealand for AML and lymphomas are also slightly lower
than population rates up to the 10th year posttransplant. Late deaths from transplant and disease-related
causes are unusual, but continue to occur for many years post-HCT.
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[1]. Allogeneic HCT recipients experience high levels
of mortality in the first few years posttransplant from
complications such as infections, organ failure, graft-
versus-host disease (GVHD), and disease relapse or
progression [1]. AutologousHCT recipients, although
experiencing lower levels of treatment-related mortal-
ity (TRM) in the first year posttransplant, continue to
be at risk for disease relapse many years posttransplant
[2-4].
Mortality risk decreases markedly for patients who
survive longer than 2 years after transplantation [2-7].
Long-term HCT survivors are at greater risk of devel-
oping new malignancies than the general population
[8-11], and are also at risk from chronic GVHD
(cGVHD), disease relapse, and other complications
[5,12-15]. Whether the life expectancy of long-term
HCT survivors ever returns to that of the general pop-
ulation is unclear [16-18].1323
1324 Biol Blood Marrow Transplant 15:1323-1330, 2009I. N. -Smith et al.In a study conducted by the International Bone
Marrow Transplant Registry, Socie et al. [16] analyzed
a group of 6691 allogeneic HCT recipients who were
transplanted between 1980 and 1993 and were free of
their original disease 2 years posttransplant [16]. The
authors produced estimates of relative mortality using
age, sex, and nationality-specific mortality rates for all
countries represented in their database. Survival rates
for the study group converged with general population
rates in the sixth year post-HCT for aplastic anemia
(AA) patients and ninth year posttransplant for acute
myelogenous leukemia (AML).
In a study of 854 autologous HCT recipients
transplanted between 1981 and 1998 and free of dis-
ease 2 years post-HCT, Bhatia et al. [17] found that
mortality rates for the study group approached popu-
lation levels at the 10th year post-HCT for patients
at standard risk for relapse and those with AML. In
a later study of allogeneic recipients, Bhatia et al. [5]
found that relative mortality decreased with time, but
remained significantly higher than population rates
15 years after HCT. A study of allogeneic HCT, car-
ried out in a single Canadian institution between
1970 and 2002, also found that mortality rates for
the study group approached population levels at the
10th year post-HCT [18]. In a matched case-con-
trolled study Syrjala et al. [19] found that 10-year
HCT survivors reported significantly more health
problems than healthy controls.
It is likely that the mortality profile of 5-year HCT
survivors differs from that of 2-year survivors because
of changes in the effects of long-term morbidities re-
sulting from cGVHD, organ damage, drug toxicities,
and other transplant-related complications. An exami-
nation of mortality patterns among 5-year HCT survi-
vors would provide valuable insight into the question
of whether the mortality of long-term HCT survivors
ever returns to normal population levels.
The objective of this study was to determine the
annual long-term mortality rates of allogeneic and au-
tologous recipients who had survived 5 years or more
disease-free post-HCT, evaluate differences inmortal-
ity between allogeneic and autologous transplant sur-
vivors, and examine their relative survival rates.PATIENTS AND METHODS
Records for HCT recipients were selected from
the database maintained by the Australasian Bone
Marrow Transplant Recipient Registry (ABMTRR),
which has captured close to 100% of HCT activity
in Australia since 1992, and New Zealand since 1998
[20]. The data available for analysis included informa-
tion on recipient age and sex, type of transplant, indi-
cation for transplant, relapse and survival status, death,
and cause of death.Patients were selected for inclusion in this study if
they had a first allogeneic, syngeneic, or autologous
HCT in Australia or New Zealand between January 1,
1992, and December 2001, 31, recorded on the
ABMTRR, and were known to have survived, disease
free, 5 years or more posttransplant. The close-out
date for this study was December 31, 2007. To limit
data variability, the study subjects were further limited
to those transplanted for specific disease types that
were represented in large numbers. For allogeneic
(including syngeneic) HCT, these were acute lympho-
blastic leukemia (ALL),AML, chronicmyelogenous leu-
kemia (CML), and myelodysplastic syndromes (MDS).
For autologous HCT, patients diagnosed with AML,
Hodgkin lymphoma (HL), multiple myeloma (MM),
and non-Hodgkin lymphoma (NHL) were selected.
Survival status for HCT recipients on the
ABMTRR is updated annually via follow-up requests
sent to each contributing center, and via data linkage
requests to the Australian National Deaths Index
(NDI), administered by the Australian Institute of
Health and Welfare (AIHW). The most recent NDI
request was carried out in 2006. In December 2007,
the ABMTRR held records for 8730 HCT performed
between 1992 and 2001, 8277 (95%) of which had
known survival status and follow-up dates (ABMTRR,
unpublished).
All analyses were performed using Stata statistical
software Release 10 (Statacorp LP, College Station,
TX, 2007). Differences between Kaplan-Meier curves
were assessedusing log-rank tests.Cumulative incidence
curves for mortality were constructed treating death
from relapse or recurrence of the underlying disease
and death from nonrelapse causes as competing risks.
Mortality in the study groupwas compared to stan-
dard Australian and New Zealand populations using
the method of relative survival [21-23]. Relative sur-
vival analysis compares mortality rates of a study group
with the general population on a year-by-year basis,
using population life tables and adjusting for factors
that have an influence on survival. Interval-specific an-
nual relative survival ratios were calculated using the
strs routine written byDickman et al. [23] in Stata soft-
ware. This routine uses actuarial methods and displays
the results in life tables stratified by the variables spec-
ified. The estimates were produced using Ederer II pa-
rameters. In this analysis, relative survival ratios were
adjusted for year of transplant, sex, age group, and
country (Australia/New Zealand). Relative survival ra-
tios are expressed as numbers or percentages; for ex-
ample, a relative survival ratio of 0.97 indicates that
the survival probability for study patients in that year
is 97% as high as that of the general population.
Life tables for 1992 to 2004 for Australia and for
1992 to 1999 for New Zealand were downloaded
from the Human Mortality database [24]. Current
life tables (not available from this source) were
Allogeneic n = 2858 Autologous n = 5419
Recipient transplanted for the
indications of ALL, AML, CML or MDS.
N = 2107
Recipient transplanted for the
indications of AML, Hodgkin
lymphoma or NHL. N = 3814
Recipient survived for 5 years or more.
N = 854
Recipient survived for 5 years or more.
N = 1448
Recipient survived, disease free, for 5
years or more. N = 688
Recipient survived, disease free, for 5
years or more. N = 773
First HCT performed between 1992 and 2001 with known survival status and follow-up
dates. N = 8277
Figure 1. Patient selection.
Biol Blood Marrow Transplant 15:1323-1330, 2009 1325Relative Survival of Long-Term Hematopoietic Cell Transplant Recipientsobtained from the relevant statistics authorities. Life
tables for 2005 and 2006 for Australia were obtained
from theWeb site of the Australian Bureau of Statistics
(ABS) [25]. Life tables for 2000 to 2002 for New
Zealand were obtained from the Web site of Statistics
New Zealand [26]. The New Zealand life table
for 2002 was the latest available, and was used for
subsequent years 2003 to 2006.
Cox regression analyses were performed separately
on allogeneic and autologous recipients to test selected
independent variables for significant associations with
mortality risk. The following binary variables were
tested for significant associations with mortality risk:
aged 50 years or above at transplant, peripheral blood
stem cells (PBSCs) as the graft source, poor risk status
at transplant (ALL and AML recipients transplanted
past first remission, and CML recipients transplanted
past first chronic phase), and for the allogeneic regres-
sion only, reduced-intensity conditioning (RIC), 1 or
more HLA mismatch, and nonsibling donor.Table 1. Six- to 10-Year Survival Probabilities (%) for 5-Year
Survivors
Years Posttransplant
N 6 7 8 9 10
Allogeneic
ALL 180 99.4 97.1 94.5 94.5 94.5
AML 207 98.9 98.9 98.1 93.1 92.0
CML 246 98.6 97.6 96.3 94.8 94.8
MDS 55 98.1 95.9 92.9 89.0 89.0
Total allogeneic 688 99.0 97.7 96.3 94.0 93.4
Autologous
AML 176 98.8 97.9 96.3 94.2 94.2
Hodgkin lymphoma (HL) 149 96.9 94.9 94.9 94.9 94.9
NHL 448 97.7 95.5 92.0 87.7 86.1
Total AML, HL, NHL 773 97.8 96.0 93.6 90.6 89.6
Multiple myeloma 207 95.3 88.9 80.5 75.5 67.4
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous
leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic
syndrome; NHL, non-Hodgkin lymphoma.RESULTS
Study subjects were selected from a total of 8277
first transplants performed between 1992 and 2001,
with known survival status and follow-up dates (Fig-
ure 1). Of the 2858 allografts, 2107 were for ALL,
AML, CML, or MDS, whereas 751 were for other
less common indications and were excluded from the
analysis. There were 5419 autografts; 3814 were per-
formed for AML, HL, NHL, or MM, and 1605 were
for less common indications and were excluded from
this study. A total of 688 allogeneic recipients who
were transplanted for ALL, AML, CML, or MDS,
and had survived for 5 years disease-free post-HCT
were selected (Figure 1). The median follow-up time
for these recipients was 8.25 years post-HCT, and
the 6- to 10-year survival probabilities were not signif-
icantly different between the 4 selected disease types
(P5 .5; Table 1). A total of 773 autologous HCTrecipients transplanted for AML, HL, or NHL were
selected; these patients had a median follow-up time
of 7.7 years and the difference in survival probability
between the 3 indications was not significant
(P5 .1). An additional 207 autologous recipients
transplanted for MM were excluded from the analysis
as their 6- to 10-year survival was significantly worse
(P\ .001) than that of the other 3 diagnoses (Table
1). The lack of plateau in the survival curve of these
MM patients demonstrated that they were at continu-
ing risk of death many years posttransplant, a result
consistent with published studies [27,28].
Tables 2, 3, and 4 show characteristics of the allo-
geneic and autologous groups, excluding autografts for
MM. Both groups displayed a broad representation
across sex group, country of transplant, age, and year
of transplant. A small number of allogeneic HCT
survivors (n5 13) had RIC regimens pretransplant
(Table 2).
The 10-year survival probability for 5-year alloge-
neic HCT survivors was slightly higher than that of
5-year autologous survivors (93.4% versus 89.6%,
P5 .06; Figure 2).
Table 2. Characteristics of 5-Year Transplant Survivors by
Transplant Type
Allogeneic Autologous Total
N 688 773 1461
Indication for transplant (n, %)
ALL 180 (26%) — 180 (12%)
AML 207 (30%) 176 (23%) 383 (26%)
CML 246 (36%) — 246 (17%)
Hodgkin lymphoma — 149 (19%) 149 (10%)
MDS 55 (8%) — 55 (4%)
NHL — 448 (58%) 448 (31%)
Recipient sex (n, %)
Male 395 (57%) 462 (60%) 857 (59%)
Female 293 (43%) 311 (40%) 604 (41%)
Country of transplant (n, %)
Australia 593 (86%) 681 (88%) 1,274 (87%)
New Zealand 95 (14%) 92 (12%) 187 (13%)
Recipient median age at transplant
Median age (years) 32 41 36
Recipient age in years at transplant (n, %)
Under 16 156 (23%) 86 (11%) 242 (17%)
16 to 39 329 (48%) 274 (35%) 603 (41%)
40 to 49 148 (22%) 190 (25%) 338 (23%)
50 to 59 55 (8%) 155 (20%) 210 (14%)
60 and over — 68 (9%) 68 (5%)
Year of transplant (n, %)
1992-1993 132 (19%) 128 (17%) 260 (18%)
1994-1995 127 (18%) 164 (21%) 291 (20%)
1996-1997 166 (24%) 215 (28%) 381 (26%)
1998-1999 167 (24%) 161 (21%) 328 (22%)
2000-2001 96 (14%) 105 (14%) 201 (14%)
Cell source (n, %)
Marrow 524 (76%) 166 (21%) 690 (47%)
Peripheral blood 142 (21%) 540 (70%) 682 (47%)
Marrow + peripheral blood 8 (1%) 67 (9%) 75 (5%)
Cord blood 14 (2%) — 14 (1%)
Donor relation: allogeneic only (n, %)
Identical twin 4 (1%)
Sibling 509 (74%)
Other relative 48 (7%)
Unrelated 127 (18%)
Donor HLA match: allogeneic only (n, %)
HLA-identical (6/6) 636 (92%)
1 HLA mismatch 43 (6%)
>1 HLA mismatch 9 (1%)
Conditioning type: allogeneic only (n, %)
Myeloablative 675 (98%)
Reduced intensity 13 (2%)
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous
leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic
syndrome; NHL, non-Hodgkin lymphoma.
Table 3. Characteristics of 5-Year Allogeneic Transplant
Survivors by Disease
ALL AML CML MDS
N 180 207 246 55
Good/poor risk (n, %)
Good risk 76 (42%) 129 (62%) 215 (87%) —
Poor risk 104 (58%) 78 (38%) 31 (13%) —
Recipient sex (n, %)
Male 116 (64%) 101 (49%) 147 (60%) 31 (56%)
Female 64 (36%) 106 (51%) 99 (40%) 24 (44%)
Country of transplant (n, %)
Australia 148 (82%) 179 (86%) 215 (87%) 51 (93%)
New Zealand 32 (18%) 28 (14%) 31 (13%) 4 (7%)
Recipient median age in years at transplant
Median age 13 33 38 32
Recipient age in years at transplant (n, %)
Under 16 96 (53%) 34 (16%) 9 (4%) 17 (31%)
16 to 39 74 (41%) 106 (51%) 128 (52%) 21 (38%)
40 to 49 9 (5%) 51 (25%) 78 (32%) 10 (18%)
50 to 59 1 (1%) 16 (8%) 31 (13%) 7 (13%)
Year of transplant (n, %)
1992-1993 26 (14%) 39 (19%) 56 (23%) 11 (20%)
1994-1995 36 (20%) 34 (16%) 46 (19%) 11 (20%)
1996-1997 35 (19%) 58 (28%) 57 (23%) 16 (29%)
1998-1999 55 (31%) 44 (21%) 58 (24%) 10 (18%)
2000-2001 28 (16%) 32 (15%) 29 (12%) 7 (13%)
Cell source (n, %)
Marrow 140 (78%) 148 (71%) 190 (77%) 46 (84%)
Peripheral blood 29 (16%) 54 (26%) 51 (21%) 8 (15%)
Marrow + peripheral blood 1 (1%) 1 (0%) 5 (2%) 1 (2%)
Cord blood 10 (6%) 4 (2%) 0 (0%) 0 (0%)
Donor relation (n, %)
Identical twin 1 (1%) 1 (0%) 2 (1%) 0 (0%)
Sibling 118 (66%) 168 (81%) 182 (74%) 40 (73%)
Other relative 17 (9%) 10 (5%) 16 (7%) 6 (11%)
Unrelated 44 (24%) 28 (14%) 46 (19%) 9 (16%)
Donor HLA match (n, %)
HLA-identical (6/6) 163 (91%) 191 (92%) 231 (94%) 51 (93%)
1 HLA mismatch 12 (7%) 14 (7%) 13 (5%) 4 (7%)
>1 HLA mismatch 5 (3%) 2 (1%) 2 (1%) 0 (0%)
Conditioning type (n, %)
Myeloablative 179 (99%) 198 (96%) 244 (99%) 54 (98%)
Reduced intensity 1 (1%) 9 (4%) 2 (1%) 1 (2%)
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous
leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic
syndrome.
Good risk: ALL or AML in first remission; CML in first chronic phase.
Poor risk: ALL or AML past first remission; CML past first chronic phase.
1326 Biol Blood Marrow Transplant 15:1323-1330, 2009I. N. -Smith et al.A total of 93 deaths were recorded among the study
subjects. The predominant causes of death among au-
tologous recipients were new malignancy and relapse/
recurrence of the original disease, whereas among allo-
geneic recipients the largest numbers of deaths re-
corded were for new malignancy, infections, and
GVHD (Table 5).
The 10-year cumulative incidence of mortality
among allogeneic 5-year survivors was 6.6%, the ma-
jor component of which was nonrelapse mortality
(NRM) (5.6%; Figure 3). Relapse-related mortality
was 3.4% among 5-year autologous survivors at 10
years compared with 1.0% for allogeneic survivors,
which contributed to the overall higher 10-year mor-tality in this group (10.4% versus 6.6%, P5 .06;
Figure 4).
Figure 5 displays year-by-year relative survival ra-
tios of allogeneic HCT recipients with 95% upper and
lower confidence intervals. The survival rate of the
general Australian andNewZealand population is rep-
resented by 1 on the y-axis. Ratios of\1 indicate that
the relative survival of allogeneic survivors in that year
was lower than the general population. The relative
survival of allogeneic 5-year survivors was significantly
lower than ‘‘normal’’ in every instance between 6 and
10 years posttransplant, with the ratios varying be-
tween a low of 0.978 at 9 years posttransplant and
a high of 0.995 at 10 years posttransplant, signifying
that the patient group’s relative survival was 99.5%
of the value of the general population at that time.
There was no obvious pattern of either improvement
Table 4. Characteristics of 5-Year Autologous Transplant
Survivors by Disease
AML Hodgkin’s lymphoma NHL
N 176 149 448
Recipient sex (n, %)
Male 94 (53%) 84 (56%) 284 (63%)
Female 82 (47%) 65 (44%) 164 (37%)
Country of transplant (n, %)
Australia 146 (83%) 131 (88%) 404 (90%)
New Zealand 30 (17%) 18 (12%) 44 (10%)
Recipient median age at transplant
Median age (years) 28 31 46
Recipient age in years at transplant (n, %)
Under 16 69 (39%) 5 (3%) 12 (3%)
16 to 39 38 (22%) 107 (72%) 129 (29%)
40 to 49 27 (15%) 28 (19%) 135 (30%)
50 to 59 34 (19%) 8 (5%) 113 (25%)
60 and over 8 (5%) 1 (1%) 59 (13%)
Year of transplant (n, %)
1992-1993 50 (28%) 24 (16%) 54 (12%)
1994-1995 41 (23%) 36 (24%) 87 (19%)
1996-1997 40 (23%) 40 (27%) 135 (30%)
1998-1999 32 (18%) 34 (23%) 95 (21%)
2000-2001 13 (7%) 15 (10%) 77 (17%)
Cell source (n, %)
Marrow 97 (55%) 19 (13%) 50 (11%)
Peripheral blood 44 (25%) 118 (79%) 378 (84%)
Marrow + peripheral blood 35 (20%) 12 (8%) 20 (4%)
AML indicates acute myelogenous leukemia; NHL, non-Hodgkin
lymphoma.
Table 5. Deaths after 5 Years Posttransplant
Allogeneic Autologous Total
Number of deaths 37 56 93
Deaths by year post transplant (n, %)
Year 6 6 (16%) 15 (27%) 21 (23%)
Year 7 7 (19%) 10 (18%) 17 (18%)
Year 8 6 (16%) 11 (20%) 17 (18%)
Year 9 8 (22%) 11 (20%) 19 (20%)
Year 10 + 10 (27%) 9 (16%) 19 (20%)
Deaths by primary cause (n,%)
New malignancy (1) 9 (24%) 16 (29%) 25 (27%)
Relapse/recurrence 4 (11%) 16 (29%) 20 (22%)
Infection 5 (14%) 5 (9%) 10 (11%)
Organ—pulmonary/respiratory 4 (11%) 2 (4%) 6 (6%)
GVHD 5 (14%) — 5 (5%)
Organ—cardiac/vascular 2 (5%) 3 (5%) 5 (5%)
Hemorrhage/TTP (2) 1 (3%) 2 (4%) 3 (3%)
Accidental death 1 (3%) 1 (2%) 2 (2%)
Other (3) 2 (5%) 2 (4%) 4 (4%)
Unknown 4 (11%) 9 (16%) 13 (14%)
GVHD indicates graft-versus-host disease; TTP, thrombocytopenic pur-
pura; AML, acute myelogenous leukemia; MDS, myelodysplastic syn-
drome.
1: Allogeneic: brain tumor (2), bowel/colon (2), other (4). Autologous:
AML (5), brain tumor (2), lung (2), MDS (2), other (5).
2: Thrombotic thrombocytopenic purpura.
3: Allogeneic: graft failure/rejection (1), multiple organ failure (1). Autol-
ogous: organ—liver (1)
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displayed years.
Similar to allogeneic results, the relative survival of
autologous recipients was slightly below the popula-
tion average from 6 to 10 years posttransplant
(Figure 6). The ratios varied from a low of 0.973 in
the ninth year posttransplant, to 0.993 (ie, 99.3% of
the population value) in the 10th year posttransplant.0.0
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Figure 2. Six- to 10-year survival probabilities for 5-year allogeneicAs with allogeneic recipients, there was no discernible
pattern over the years.
Cox regression analyses for overall survival (OS)
were performed separately on the allogeneic and autol-
ogous recipient datasets. In both models, older age
(501) was an adverse mortality risk factor. For alloge-
neic recipients, peripheral blood as a graft source was
also an independent mortality risk factor (Table 6).387 295 247
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Six- to 10-year mortality among the survivors ana-
lyzed in this study appeared to have stabilized at levels
close to, but consistently lower than, those of the gen-
eral population. This finding contrasts with previous
studies of 2-year survivors, which found that survival
approached then attained the population average sev-
eral years posttransplant [5,16-18].
The 10-year cumulative NRM in this study was
similar for allogeneic (5.6%) and autologous (7.0%)
survivors, comprising mainly deaths from new malig-
nancies, organ damage or failure, infection, and
GVHD, suggesting that the main period of increased
risk of death from GVHD and infection after alloge-
neic transplantation is in the first 5 years. However,
cumulative relapse-related mortality incidence at 10
years was lower for allogeneic (1.0%) than autologous
(3.4%) survivors, suggesting a protective effect from
long-term allo immune graft-versus-malignancy ef-
fects in allograft survivors among patients transplanted
for the diseases represented in this study.
The 10-year Kaplan-Meier survival probability of
67.4% for MM autograft recipients was significantly0%
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Figure 4. Six- to 10-year cumulative incidence of relapse and NRM for
5-year autologous HCT survivors.lower than that of the other diseases studied (89.6%)
and the lack of plateau in the survival curve shows
that mortality among these patients did not lessen
over time. Of 36 6- to 10-year deaths to 207 5-year sur-
vivors, 25 (69%) were because of relapse or newmalig-
nancy, indicating that most long-term deaths in this
group could be attributed to disease rather than trans-
plant-related causes.
The relative survival rates of both allogeneic and
autologous long-term survivors were slightly lower
than the population level (ie, 1) between 6 and 10 years
posttransplant. There was no obvious pattern of
increase in relative survival rates over this time among
either allogeneic or autologous survivors.0.90
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Figure 6. Annual relative survival ratios of autologous recipients with
95% confidence intervals, 6 to 10 years posttransplant. Note: the sur-
vival rate of the general Australian and New Zealand population is rep-
resented by 1 on the y-axis. Relative survival ratios are expressed as
numbers; a relative survival ratio of 0.97 indicates that the survival prob-
ability for study patients in that year is 97% as high as that of the general
population.
Table 6. Significant Risk Factors for ReducedOverall Survival
from Multivariate Cox Regressions
Variable
Hazard
ratio
Lower
95% CI
Upper
95% CI P
Allogeneic (n5 688)
Recipient aged 50 years and above (1) 2.56 1.12 5.87 .03
Cell source peripheral blood (2) 3.70 1.75 7.81 .001
Autologous (n5 773)
Recipient aged 50 years and above (1) 2.80 1.66 4.73 <.001
Note: reference categories for independent variables:
1Recipient aged less than 50 years.
2Cell source marrow, marrow plus peripheral blood (PB) or cord blood.
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Australia is 78.7 for males and 83.5 for females [25],
and, respectively, 76.3 for males and 81.1 for females
in New Zealand [26]. The results discussed here apply
only to Australia and New Zealand, but can be cau-
tiously compared to other developed countries with
similar demographic features and health systems.
The patient population was comparatively young
(median age 36 years), and this has been taken into ac-
count in the relative survival calculation, which is age
adjusted. Follow-up to 10 years was carried out using
a data linkage with the Australian NDI, so incomplete
follow-up has been kept to a minimum.
The reason for the different results between this
and previous reports may lie in the nature of the groups
studied. Previous studies analyzed results from 2-year
survivors transplanted no later than 1998. Compared
to these patient groups, the recipients included in
this study were a comparatively smaller proportion of
the original number (Figure 1), were transplanted
more recently, and had longer initial survival times.
It can be surmised that among the 5-year HCT survi-
vors in this study, mortality risk from disease recur-
rence and chronic morbidities had stabilized.
Cox regression analyses indicated that increased age
(.50 years) at transplant was a significant adverse risk
factor for both allogeneic and autologous long-termsur-
vivors of the diseases represented in this study. Several
previous studies found that increased age was not a
short-term survival risk factor post-HCT [29–32], but
it appears that the older recipients in this study may
have been more susceptible to the effects of long-term
transplant complications, in addition to the inevitable
increase in mortality because of their advancing age.
The relationship of PBSC as graft source to inci-
dence of cGVHD and long-term survival of allograft
recipients remains a relevant research issue. In a com-
bined Center for International Blood and Marrow
Transplant Research (CIBMTR)/European Blood
and Marrow Transplant (EBMT) study, Schmitz
et al. [33] found that cGVHD was more frequent after
PBSC compared to bone marrow (BM) transplanta-
tion [33], but leukemia-free survival (LFS) rates wereonly lower for those PBSC recipients who were in first
chronic phase of CML at transplant. In another large
study, Eapen and colleagues [34] found that PBSC
grafts from unrelated donors were associated with in-
creased acute GVHD (aGVHD) and cGVHDwithout
improved survival [34]. In contrast, Schrezenmeier and
colleagues [35] found higher levels of cGVHD and
worse outcome among HLA-matched sibling donor
transplants for young patients with severe acquired
aplastic anemia.
The finding in this study that PBSC as a graft
source is an adverse survival risk factor in long-term al-
logeneic survivors may be attributed to the debilitating
effect of cGVHD, the incidence of which is known
to be higher in these recipients [34,35]. However,
cGVHD status was not available for this analysis so
its effect cannot be directly determined.
This study indicates that annual mortality rates of
long-term survivors of allogeneic HCT for the dis-
eases of ALL, AML, CML, and MDS, and autologous
HCT for the diseases of AML, HL, and NHL ap-
proach population rates in Australia and New Zealand
from 6 years posttransplant onward, but occasional
deaths from transplant-related causes or late disease
recurrence still occur for many years. Further research
would be needed to verify that these findings apply to
other disease groups treatable by HCT. Resources for
support of long-term HCT survivors should be set at
appropriate levels given the continuing increase in
numbers of long-term HCT survivors. Regular con-
tacts through annual late effects clinics and other ar-
rangements should be given high priority, given
relatively high rates of NRM in these long-term survi-
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